KR20220023343A - 단백질 표적 화합물, 이의 약학 조성물 및 이들의 치료적 적용 - Google Patents

단백질 표적 화합물, 이의 약학 조성물 및 이들의 치료적 적용 Download PDF

Info

Publication number
KR20220023343A
KR20220023343A KR1020217039259A KR20217039259A KR20220023343A KR 20220023343 A KR20220023343 A KR 20220023343A KR 1020217039259 A KR1020217039259 A KR 1020217039259A KR 20217039259 A KR20217039259 A KR 20217039259A KR 20220023343 A KR20220023343 A KR 20220023343A
Authority
KR
South Korea
Prior art keywords
methyl
optionally substituted
dioxopiperidin
oxo
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217039259A
Other languages
English (en)
Korean (ko)
Inventor
카일 더블유.에이치. 찬
폴 이. 어드만
레아 펑
데이비드 아론 헥트
아파라지타 호스코테 쿠라시아
이멜다 램
프랭크 머큐리오
로버트 설리반
에두아르도 토레스
Original Assignee
바이오테릭스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오테릭스, 인코포레이티드 filed Critical 바이오테릭스, 인코포레이티드
Publication of KR20220023343A publication Critical patent/KR20220023343A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020217039259A 2019-05-24 2020-05-22 단백질 표적 화합물, 이의 약학 조성물 및 이들의 치료적 적용 Withdrawn KR20220023343A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852844P 2019-05-24 2019-05-24
US62/852,844 2019-05-24
PCT/US2020/034264 WO2020242960A1 (en) 2019-05-24 2020-05-22 Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications

Publications (1)

Publication Number Publication Date
KR20220023343A true KR20220023343A (ko) 2022-03-02

Family

ID=71092611

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217039259A Withdrawn KR20220023343A (ko) 2019-05-24 2020-05-22 단백질 표적 화합물, 이의 약학 조성물 및 이들의 치료적 적용

Country Status (14)

Country Link
US (2) US11345712B2 (https=)
EP (1) EP3976623A1 (https=)
JP (1) JP2022533260A (https=)
KR (1) KR20220023343A (https=)
CN (1) CN114502543A (https=)
AU (1) AU2020283744A1 (https=)
CA (1) CA3140078C (https=)
EA (1) EA202192910A1 (https=)
IL (1) IL288204A (https=)
MX (1) MX2021014345A (https=)
SG (1) SG11202112355VA (https=)
TW (1) TW202110818A (https=)
WO (1) WO2020242960A1 (https=)
ZA (1) ZA202109124B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
MX2022006133A (es) * 2019-12-06 2022-06-17 Celgene Corp Procesos para preparar 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin- 3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
WO2021119571A1 (en) * 2019-12-12 2021-06-17 Biotheryx, Inc. Pde4 inhibitors, pharmaceutical compositions, and therapeutic applications
WO2021126973A1 (en) * 2019-12-17 2021-06-24 Orionis Biosciences, Inc. Compounds modulating protein recruitment and/or degradation
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
JP2023545274A (ja) * 2020-10-07 2023-10-27 クルゲン(シャンハイ),インク. 癌を処置する化合物および方法
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CN117203196A (zh) 2020-12-14 2023-12-08 拜欧斯瑞克斯公司 Pde4降解剂、药物组合物和治疗应用
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
AU2022253450A1 (en) * 2021-04-05 2023-11-16 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
CA3221549A1 (en) * 2021-06-08 2022-12-15 Liqiang Fu Isoindolinone compounds, and uses thereof
US20240368113A1 (en) * 2021-06-28 2024-11-07 Chengdu Fendi Pharmaceutical Co. Ltd. Amide compound and use thereof
JP2024527628A (ja) * 2021-07-19 2024-07-25 メッドシャイン ディスカバリー インコーポレイテッド ヘテロアリール-3-ピペリジンジオン化合物その使用
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023070120A1 (en) * 2021-10-22 2023-04-27 Biotheryx, Inc. Ketoamides for treating malignancy
WO2023069708A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and uses thereof
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
KR20240123836A (ko) * 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN114835680A (zh) * 2022-04-29 2022-08-02 成都分迪药业有限公司 卤素取代异吲哚啉化合物及其应用
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
EP4584259A1 (en) * 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024167423A1 (en) * 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds
WO2024222918A1 (zh) * 2023-04-28 2024-10-31 中国药科大学 一种苯并六元杂环类gspt1蛋白降解剂及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
EP2197552B1 (en) * 2007-09-19 2012-11-21 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
SG11201805779TA (en) * 2016-01-08 2018-08-30 Celgene Corp Antiproliferative compounds, and their pharmaceutical compositions and uses
WO2017201069A1 (en) * 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
KR101825065B1 (ko) * 2016-05-24 2018-02-05 한국화학연구원 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN108069959A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
US10040804B2 (en) 2016-12-21 2018-08-07 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
US10406165B2 (en) 2017-03-14 2019-09-10 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
CN108929307A (zh) * 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
EP3784665A4 (en) * 2018-04-26 2022-01-26 Aurigene Discovery Technologies Limited PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS
CA3101338A1 (en) 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
CA3106239A1 (en) * 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators

Also Published As

Publication number Publication date
JP2022533260A (ja) 2022-07-21
EA202192910A1 (ru) 2022-03-18
MX2021014345A (es) 2022-01-06
ZA202109124B (en) 2023-10-25
CN114502543A (zh) 2022-05-13
US20200369679A1 (en) 2020-11-26
US11345712B2 (en) 2022-05-31
AU2020283744A1 (en) 2021-12-09
US20220298172A1 (en) 2022-09-22
TW202110818A (zh) 2021-03-16
IL288204A (en) 2022-01-01
EP3976623A1 (en) 2022-04-06
CA3140078A1 (en) 2020-12-03
CA3140078C (en) 2023-11-28
WO2020242960A1 (en) 2020-12-03
SG11202112355VA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
US11345712B2 (en) Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications
JP7050879B2 (ja) ピラゾール化合物ならびにこの化合物を作製および使用するための方法
TWI647214B (zh) 雙環稠合之雜芳基或芳基化合物類
CN102300862B (zh) 用作atr激酶抑制剂的化合物
CN101883764B (zh) 吡唑衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途
US9133187B2 (en) Serine/threonine kinase inhibitors
CN107849055B (zh) 用作irak1/4抑制剂的大环化合物及其用途
KR100714154B1 (ko) 트리아자스피로[5.5]운데칸 유도체 및 이들을유효성분으로 하는 약제
EP2976341B1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
KR20190093205A (ko) 단백질 표적화에 사용하기 위한 티에노피롤 유도체, 조성물, 방법 및 이의 용도
US20180237413A1 (en) Heteroaryl compounds as irak inhibitors and uses thereof
JP2021527098A (ja) 縮合チオフェン化合物
BRPI0407827B1 (pt) Compostos de aminoeteroarila como inibidores de proteína cinase e respectivos usos
JP2009538352A (ja) 細胞増殖を阻害するための薬剤としての2−カルボシクロアミノ−4−イミダゾリルピリミジン類
KR20190003687A (ko) 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
CN112313236A (zh) 噻吩并嘧啶酮化合物
KR20190003685A (ko) 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
KR20230035311A (ko) Nek7 키나제의 억제제
KR20080033450A (ko) 증식성 질환의 치료에 사용하기 위한 이미다졸릴-피리미딘화합물
CN102227429B (zh) 作为趋化因子受体调节剂的3-氨基环戊烷羧酰胺
CN107207476A (zh) 吲哚和氮杂吲哚衍生物及其用于神经退化性疾病中的用途
US11407831B2 (en) Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent
HK1247918B (zh) 用作irak1/4抑制剂的大环化合物及其用途
EA047011B1 (ru) Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы
HK1162482B (en) Pyrazine derivatives useful as inhibitors of atr kinase

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20211130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20240620

WITB Written withdrawal of application